Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features.

Trial Profile

Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Chronic lymphocytic leukaemia; Pneumococcal infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 19 Jan 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
    • 19 Jan 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top